| Host: |
HEK293 cells |
| Reactivity: |
Human |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Recombinant-Human IL-7-C-His protein was developed from hek293 cells and has a target region of C-His. For use in research applications. |
| Formulation: |
Lyophilized from a 0.22 Mu m filtered solution of PBS, pH 7.4. Contact us for customized product form or formulation. |
| Immunoreactivity: |
Measured by its binding ability in a functional ELISA. Immobilized Human IL7 at 2 Mu g/mL (100 Mu L/well) can bind human IL7R with a linear range of 0.97-159.1 ng/mL.2. Measured in a cell proliferation assay using IL-2-activated mouse spleen cell. Th |
| Gene Symbol: |
IL7 |
| Gene ID: |
3574 |
| Uniprot ID: |
IL7_HUMAN |
| Immunogen Region: |
Asp26-His177 |
| Immunogen: |
Active Recombinant Human IL-7 Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Asp26-His177) of human IL-7 (Accession #NP_000871.1) fused with a 6×His tag at the C-terminus. |
| Function | Hematopoietic cytokine that plays an essential role in the development, expansion, and survival of naive and memory T-cells and B-cells thereby regulating the number of mature lymphocytes and maintaining lymphoid homeostasis. Mechanistically, exerts its biological effects through a receptor composed of IL7RA subunit and the cytokine receptor common subunit gamma/CSF2RG. Binding to the receptor leads to activation of various kinases including JAK1 or JAK3 depending on the cell type and subsequently propagation of signals through activation of several downstream signaling pathways including the PI3K/Akt/mTOR or the JAK-STAT5. |
| Protein Name | Interleukin-7Il-7 |
| Database Links | Reactome: R-HSA-1266695 |
| Cellular Localisation | Secreted |
| Alternative Protein Names | Interleukin-7 proteinIl-7 proteinIL7 protein |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
